4D Molecular Therapeutics, Inc.
NASDAQ:FDMT
8.28 (USD) • At close November 7, 2024
Overview | Financials
Numbers are in millions (except for per share data and ratios) USD.
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | |
|---|---|---|---|---|---|---|---|
| Assets: | |||||||
| Current Assets: | |||||||
| Cash & Cash Equivalents
| 249.108 | 218.642 | 315.429 | 276.726 | 49.652 | 91.761 | 23.85 |
| Short Term Investments
| 39.124 | 161.203 | 94.776 | 0 | 0 | 0 | 0 |
| Cash and Short Term Investments
| 288.232 | 218.642 | 315.429 | 276.726 | 49.652 | 91.761 | 23.85 |
| Net Receivables
| 0 | 0.7 | 0.047 | 1.486 | 0.978 | 1.124 | 0.321 |
| Inventory
| 0 | -5.788 | -8.503 | 0 | 0 | 0 | 0 |
| Other Current Assets
| 8.356 | 6.957 | 8.456 | 4.444 | 1.878 | 1.183 | 0.328 |
| Total Current Assets
| 296.588 | 220.511 | 315.429 | 282.656 | 52.508 | 94.068 | 24.499 |
| Non-Current Assets: | |||||||
| Property, Plant & Equipment, Net
| 31.665 | 35.347 | 28.953 | 5.073 | 5.049 | 2.472 | 2.716 |
| Goodwill
| 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets
| 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Goodwill and Intangible Assets
| 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Long Term Investments
| 10.954 | 4.908 | 67.652 | 0 | 0 | 0 | 0 |
| Tax Assets
| 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Non-Current Assets
| 0.684 | 1.08 | -58.547 | 0.602 | 0.677 | 0.429 | 0.105 |
| Total Non-Current Assets
| 43.303 | 41.335 | 38.058 | 5.675 | 5.726 | 2.901 | 2.821 |
| Total Assets
| 339.891 | 261.846 | 353.487 | 288.331 | 58.234 | 96.969 | 27.32 |
| Liabilities & Equity: | |||||||
| Current Liabilities: | |||||||
| Account Payables
| 3.515 | 3.322 | 4.764 | 1.787 | 1.744 | 0.954 | 0.46 |
| Short Term Debt
| 3.149 | 2.655 | 1.231 | 0 | 0 | 0.093 | 0.051 |
| Tax Payables
| 0 | 0 | 0 | 0 | 0 | 0.093 | 0.051 |
| Deferred Revenue
| 0.273 | 0.884 | 2.599 | 6.586 | 5.864 | 4.907 | 4.382 |
| Other Current Liabilities
| 12.014 | 8.87 | 7.744 | 8.371 | 5.347 | 2.1 | 1.015 |
| Total Current Liabilities
| 18.951 | 15.731 | 16.338 | 16.744 | 12.955 | 8.054 | 5.908 |
| Non-Current Liabilities: | |||||||
| Long Term Debt
| 11.522 | 13.469 | 15.217 | 0 | 0 | 0 | 0 |
| Deferred Revenue Non-Current
| 0.972 | 1.076 | 2.491 | 13.226 | 13.603 | 13.076 | 22.188 |
| Deferred Tax Liabilities Non-Current
| -0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Non-Current Liabilities
| 0.617 | 0.233 | 0.334 | 1.974 | 104.646 | 103.426 | 18.814 |
| Total Non-Current Liabilities
| 13.111 | 14.778 | 18.042 | 15.2 | 118.249 | 116.502 | 41.002 |
| Total Liabilities
| 32.062 | 30.509 | 560.483 | 31.944 | 131.204 | 124.556 | 46.91 |
| Equity: | |||||||
| Preferred Stock
| 0 | 0 | 0 | 288.331 | 102.98 | 102.98 | 18.508 |
| Common Stock
| 0.004 | 0.003 | 0.003 | 0.003 | 0.001 | 0.001 | 0.001 |
| Retained Earnings
| -415.327 | -314.49 | -206.996 | -135.679 | -79.025 | -30.026 | -20.475 |
| Accumulated Other Comprehensive Income/Loss
| 0.016 | -1.196 | -0.423 | -288.331 | -102.98 | -102.98 | -18.508 |
| Other Total Stockholders Equity
| 723.136 | 1.193 | 0.42 | 392.063 | 6.054 | 2.438 | 0.884 |
| Total Shareholders Equity
| 307.829 | -314.49 | -206.996 | 256.387 | -72.97 | -27.587 | -19.59 |
| Total Equity
| 307.829 | -314.49 | -206.996 | 256.387 | -72.97 | -27.587 | -19.59 |
| Total Liabilities & Shareholders Equity
| 339.891 | -283.981 | 353.487 | 288.331 | 58.234 | 96.969 | 27.32 |